Intestinal Cell News Volume 8.03 | Jan 28 2022

    0
    30






    2022-01-28 | ICN 8.03


    Intestinal Cell News by STEMCELL Technologies
    Vol. 8.03 – 28 January, 2022
    TOP STORY

    Microbial Signals, MyD88, and Lymphotoxin Drive TNF-Independent Intestinal Epithelial Tissue Damage

    Researchers showed that TNF-independent intestinal epithelial cells death after A20 and Abin-1 deletion was rescued by germ-free derivation or deletion of MyD88, while deletion of Trif provided only partial protection.
    [Journal of Clinical Investigation]

    AbstractGraphical Abstract

    Free E-Book: Genome Editing Applications for Disease Modeling and Cell Therapy.
    PUBLICATIONSRanked by the impact factor of the journal

    Canonical TGFβ Signaling Induces Collective Invasion in Colorectal Carcinogenesis through a Snail1- and Zeb1-Independent Partial EMT

    The authors investigated the impact of oncogenic transformation and the microenvironment on tumor cell invasion using genetically engineered organoids as colorectal cancer models.
    [Oncogene]

    Full Article

    Loss of NFE2L3 Protects against Inflammation-Induced Colorectal Cancer through Modulation of the Tumor Microenvironment

    Researchers investigated the role of the NFE2L3 transcription factor in inflammation-induced colorectal cancer.
    [Oncogene]

    Full Article

    The EMT-Induced lncRNA NR2F1-AS1 Positively Modulates NR2F1 Expression and Drives Gastric Cancer via miR-29a-3p/VAMP7 Axis

    NR2F1-AS1 and NR2F1 were highly co-expressed in pan-tissues and pan-cancers. Depletion of NR2F1-AS1 compromised the expression level of NR2F1 in gastric cancer cells.
    [Cell Death & Disease]

    Full Article

    Immune Translational Control by CPEB4 Regulates Intestinal Inflammation Resolution and Colorectal Cancer Development

    Researchers addressed the contribution of posttranscriptional regulation, by the RNA-binding protein CPEB4, to intestinal immune homeostasis and its role in inflammatory bowel diseases and CRC development.
    [iScience]

    Full ArticleGraphical Abstract

    Direct Inhibition of the First PDZ Domain of ZO-1 by Glycyrrhizin Is a Possible Mechanism of Tight Junction Opening of Caco-2 Cells

    The authors first found that glycyrrhizin (GL) bound to the first PDZ domain of zonula occludens-1 through NMR experiments. They identified the relevant interactions between the glucuronate-2 moiety of GL and the carboxylate binding loop of the ligand binding site of ZO-1(PDZ1).
    [Food & Function]

    AbstractGraphical Abstract

    Combined MEK/MDM2 Inhibition Demonstrates Antitumor Efficacy in TP53 Wild-Type Thyroid and Colorectal Cancers with MAPK Alterations

    Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.
    [Scientific Reports]

    Full Article

    Intestinal Absorption Mechanism of Rotundic Acid: Involvement of P-GP and OATP2B1

    The molecular properties and the effects of principal parameters were analyzed by liquid chromatography-tandem mass spectrometry.
    [Journal of Ethnopharmacology]

    Full ArticleGraphical Abstract

    The Effects of Citrus Flavonoids and Their Metabolites on Immune-Mediated Intestinal Barrier Disruption Using an In Vitro Co-Culture Model

    Scientists assessed the effect of citrus flavonoids and their intestinal metabolites on immune-mediated barrier disruption in an in vitro co-culture model.
    [British Journal of Nutrition]

    Abstract

    Stay up-to-date with the latest stem cell research by listening to the Stem Cell Podcast!
    REVIEWS

    Wnt/β-Catenin Signaling in Colorectal Cancer: Is Therapeutic Targeting Even Possible?

    The authors reviewed the recent progress of this signal transduction pathway in colorectal tumorigenesis.
    [Biochimie]

    Full Article

    INDUSTRY AND POLICY NEWS

    Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase III Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

    Zealand Pharma A/S announced completion of patient enrollment in its pivotal Phase III trial of glepaglutide, the company’s long-acting GLP-2 analog, for the potential treatment of short bowel syndrome.
    [Zealand Pharma A/S (GlobeNewswire, Inc.)]

    Press Release

    FEATURED EVENT

    The Australasian Society for Stem Cell Research (ASSCR) Annual Meeting

    March 9 – 11, 2022
    Melbourne, Victoria, Australia

    > See All Events

    JOB OPPORTUNITIES

    Research Associate – Gastroenterology

    The University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Research Fellow – Intestinal Developmental Immunology

    University of Oxford – Oxford, England, United Kingdom

    Postdoctoral Fellow – Intestinal Inflammation

    University of North Dakota – Grand Forks, North Dakota, United States

    Research Fellow – Adenocarcinoma

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Associate – Molecular and Cellular Biology

    Baylor College of Medicine – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Intestinal Cell News Twitter